phase 2 retatrutide ๐จBreaking: Retatrutide's first 3 T2D data just dropped. โธ A1C: โ2.0% at 40 weeks โธ Weight: โ36.6 lbs (โ16.8%) at 12 mg โธ No weight loss plateau โ curve still descending Retatrutide: A Promising Option for
Description
Today, the FDA is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies including Hims &
Yerba Mate may be helpful in reducing body weight and fat
glp1 receptor agonist market trends
Ozempic, Mounjaro, Wegovy, Zepbound, Semaglutide, Tirzepatide
3-6 Week GLP Ramp-Up: Noticeable results develop gradually as gut health and metabolism improve
Board-Certified Dr
